Our Enterprise Strategy practice offers life sciences clients guidance and support in developing best in class approaches to clinical, medical and commercial operations. Putnam delivers a global team equipped to handle the complexities of identifying and executing winning global strategies. Our strategic recommendations are underpinned by rigorous evidence collection and experience in supporting leading biopharmaceutical companies for over three decades to deliver exceptional impact and value to enterprise and corporate needs.

  • Portfolio-level digital and personal promotional strategy
  • Corporate account engagement
  • Data platform & insight mining
  • R&D decision-making process optimization
  • New business unit evaluation and implementation strategy
  • Virtual commercial operations support

Supporting our Enterprise Strategy is Functional Expertise in Key Disciplines

Operations Expertise/Change Management

Understanding the HOW related to clinical asset positioning

Deep Experience & Rigorous Strategic Perspective

Drawing on Deep Expertise and Framing Issues from a Strategic Perspective to produce client impact

Top to bottom support for all areas of enterprise

Quantifying the IMPACT on commercial opportunity

Projects

  • New business unit evaluation and implementation strategy
  • Virtual analytics and insights function for emerging life sciences companies
  • Virtual commercial strategy function for emerging life sciences companies
  • Designing optimized global and operating affiliate workflows
  • Portfolio-level digital and personal promotional strategy
  • Corporate account engagement strategy
  • Data platform & insight mining strategy
  • R&D decision process strategy

Get in Touch

We partner with clients to address the most complex challenges facing the life sciences industry. Our carefully designed evidence-based strategies allow us to generate winning insights for our clients all over the globe.

How can we help you and your team?
  • This field is for validation purposes and should be left unchanged.

Strategy for the Life Sciences